SpaceOAR® Hydrogel News
New treatment reduces side-effects of radiotherapy in prostate cancer patients
Prostate cancer patients at The London Clinic are some of the first in the UK to be treated with a new high-tech gel that has been designed to protect men from the side-effects of radiotherapy treatment that can cause long-term problems such as rectal damage.
GenesisCare UK and Augmenix UK Ltd. Announce UK Partnership
GenesisCare UK and Augmenix UK Ltd. announce a partnership to provide access to SpaceOAR Hydrogel, a minimally invasive hydrogel spacer, which lasts the duration of therapy and is proven to decrease unwanted side effects from radiotherapy treatment in patients with prostate cancer.
New UK Headquarters
Augmenix, Inc., a worldwide leader in hydrogel spacing solutions which reduces toxicity associated with radiation therapy, has opened a new UK company headquarters, Augmenix UK Ltd., in Corby, Northamptonshire, England.
Prostate Cancer Radiotherapy in Japan
An Update From Stephen McGill, Vice President and General Manager International.
I am delighted that SpaceOAR hydrogel is now available through the MHLW national reimbursement programme for all men undergoing prostate cancer radiotherapy treatment throughout Japan. I truly believe the commitment of the Japanese MHLW to reimburse SpaceOAR is a substantial leap forward to improving radiotherapy outcomes and reducing the associated risks.
UsToo and Dr. Daniel Fried Present Live Webcast and Q and A on Prostate Cancer Radiation Therapy
The event featured a presentation from renowned radiation oncologist Daniel B. Fried, MD, MPH, PhD, who practices at the Gibbs Cancer Center and Research Institute in Greenville, S.C discussing radiation therapy as an option for prostate cancer treatment.
The Relaunch of SpaceOAR Hydrogel Clinical Publications!
Now it’s easier than ever to find the peer-reviewed papers, abstracts and posters that evaluate the efficacy of SpaceOAR hydrogel.